In May 2025, the New England Journal of Medicine published the first head-to-head clinical trial comparing two of the most effective anti-obesity medications on the market: tirzepatide (Zepbound) and semaglutide (Wegovy). This was the phase 3b open label extension of the SURMOUNT-5 clinical trial involving 751 non-diabetic obese patients. The main finding was that tirzepatide led to significantly more weight loss than semaglutide over 72
In the ever evolving field of weight management, two recently marketed drugs have captured significant attention: Wegovy (semaglutide) and Zepbound (tirzepatide). While originally designed to address type 2 diabetes, both medications demonstrated impressive results in overweight individuals who do not have type 2 diabetes. This post will explore what current clinical trial data tells us
The short answer: Zepbound and Wegovy lower your appetite, but they do not choose your food for you. You will get the most from either one if you eat enough protein at every meal, favor whole foods, drink fluids regularly, add strength training to your walking, and use food to manage the stomach side effects
